✦ LIBER ✦

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

✍ Scribed by Jean-Michel Molina; Pedro Cahn; Beatriz Grinsztejn; Adriano Lazzarin; Anthony Mills; Michael Saag; Khuanchai Supparatpinyo; Sharon Walmsley; Herta Crauwels; Laurence T Rimsky; Simon Vanveggel; Katia Boven

Book ID: 117308775
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 210 KB
Volume: 378
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(11)60936-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Co-formulated elvitegravir, cobicistat,

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

✍ Paul E Sax; Edwin DeJesus; Anthony Mills; Andrew Zolopa; Calvin Cohen; David Woh 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 383 KB

Rilpivirine versus efavirenz with two ba

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

✍ Calvin J Cohen; Jaime Andrade-Villanueva; Bonaventura Clotet; Jan Fourie; Margar 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 211 KB

Safety and efficacy of raltegravir-based

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

✍ Jeffrey L Lennox; Edwin DeJesus; Adriano Lazzarin; Richard B Pollard; Jose Valde 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 248 KB

Co-formulated elvitegravir, cobicistat,

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

✍ Edwin DeJesus; Jürgen K Rockstroh; Keith Henry; Jean-Michel Molina; Joseph Gathe 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 339 KB

Efficacy and safety of rilpivirine in tr

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials

✍ Nelson, M.; Amaya, G.; Clumeck, N.; Arns da Cunha, C.; Jayaweera, D.; Junod, P.; 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 261 KB

Simeprevir with pegylated interferon alf

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

✍ Jacobson, Ira M; Dore, Gregory J; Foster, Graham R; Fried, Michael W; Radu, Moni 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 284 KB